JP5598894B2 - 生物活性を強化した抗体改変体 - Google Patents

生物活性を強化した抗体改変体 Download PDF

Info

Publication number
JP5598894B2
JP5598894B2 JP2008502861A JP2008502861A JP5598894B2 JP 5598894 B2 JP5598894 B2 JP 5598894B2 JP 2008502861 A JP2008502861 A JP 2008502861A JP 2008502861 A JP2008502861 A JP 2008502861A JP 5598894 B2 JP5598894 B2 JP 5598894B2
Authority
JP
Japan
Prior art keywords
antibody
domain
minutes
spacer
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008502861A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2007100083A1 (ja
Inventor
安彦 増保
弘明 長島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Tokyo University of Science
Teijin Pharma Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Tokyo University of Science
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Tokyo University of Science, Teijin Pharma Ltd filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority to JP2008502861A priority Critical patent/JP5598894B2/ja
Publication of JPWO2007100083A1 publication Critical patent/JPWO2007100083A1/ja
Application granted granted Critical
Publication of JP5598894B2 publication Critical patent/JP5598894B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008502861A 2006-03-03 2007-03-02 生物活性を強化した抗体改変体 Expired - Fee Related JP5598894B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008502861A JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006057475 2006-03-03
JP2006057475 2006-03-03
JP2008502861A JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体
PCT/JP2007/054018 WO2007100083A1 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012004674A Division JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Publications (2)

Publication Number Publication Date
JPWO2007100083A1 JPWO2007100083A1 (ja) 2009-07-23
JP5598894B2 true JP5598894B2 (ja) 2014-10-01

Family

ID=38459178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008502861A Expired - Fee Related JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体
JP2012004674A Expired - Fee Related JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012004674A Expired - Fee Related JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Country Status (6)

Country Link
US (2) US20090304715A1 (cg-RX-API-DMAC7.html)
EP (2) EP2006305B1 (cg-RX-API-DMAC7.html)
JP (2) JP5598894B2 (cg-RX-API-DMAC7.html)
CA (1) CA2638804C (cg-RX-API-DMAC7.html)
ES (1) ES2602439T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007100083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2010065578A2 (en) * 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
WO2012002562A1 (en) * 2010-06-30 2012-01-05 Tokyo University Of Science Educational Foundation Administrative Organization Modified protein therapeutics
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
AR085404A1 (es) * 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
US9683044B2 (en) * 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
MX2015009819A (es) 2013-01-28 2015-10-29 Evec Inc Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
WO2015005960A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation Removal of fragments from a sample containing a target protein using activated carbon
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
WO2017019729A1 (en) 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
WO2018129397A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
CN119421953A (zh) 2022-01-28 2025-02-11 株式会社伊贝克 具有突变株交叉性的抗SARS－CoV－2人中和抗体及其抗原结合片段

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
DE3908834A1 (de) 1989-03-17 1990-09-20 Hollingsworth Gmbh Vorrichtung zur ausscheidung von verunreinigungen eines faserverbandes an einer karde
AU2002250293B2 (en) * 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN5010008747; ＳＴＥＶＥＮＳＯＮ　Ｇ　Ｔ: ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＬＯＧＹ Ｖ１５８, 19970101, Ｐ２２４２-２２５０, ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＯＦ　ＩＭＭＵＮＯＬＯＧＩＳＴＳ *
JPN5010008943; ＧＲＥＥＮＷＯＯＤ　Ｊ: ＴＨＥＲＡＰＥＵＴＩＣ　ＩＭＭＵＮＯＬＯＧＹ Ｖ１　Ｎ５, 19941001, Ｐ２４７-２５５, ＢＬＡＣＫＷＥＬＬ　ＳＣＩＥＮＴＩＦＩＣ　ＰＵＢＬ． *
JPN6011059765; 田村隆明，　山本雅　編: 分子生物学イラストレイテッド 第２刷, 1998, 第１５９-１６０頁 *
JPN6011059767; 長島弘明，　増保安彦: 薬学雑誌 Ｖｏｌ．１３０，　Ｎｏ．１, 2010, ｐｐ．４９-５４ *
JPN6011059770; ＫＡＮ，　Ｋ．Ｓ．　ｅｔ　ａｌ．: Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１６６, 2001, ｐｐ．１３２０-１３２６ *
JPN6012050543; ＣＡＲＴＲＯＮ，　Ｇ．　ｅｔ　ａｌ．: Ｂｌｏｏｄ Ｖｏｌ．９９, 2002, ｐｐ．７５４-７５８ *
JPN6012050545; ＷＥＮＧ，　Ｗ．-Ｋ．　ａｎｄ　ＬＥＶＹ，　Ｒ．: Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２１，　Ｎｏ．２１, 2003, ｐｐ．３９４０-３９４７ *

Also Published As

Publication number Publication date
EP2610268A1 (en) 2013-07-03
EP2006305B1 (en) 2016-08-10
US20190367630A1 (en) 2019-12-05
JPWO2007100083A1 (ja) 2009-07-23
JP5901299B2 (ja) 2016-04-06
EP2006305A4 (en) 2010-06-30
JP2012136519A (ja) 2012-07-19
CA2638804A1 (en) 2007-09-07
US20090304715A1 (en) 2009-12-10
EP2006305A2 (en) 2008-12-24
ES2602439T3 (es) 2017-02-21
EP2006305A9 (en) 2009-07-15
CA2638804C (en) 2017-02-28
WO2007100083A1 (ja) 2007-09-07

Similar Documents

Publication Publication Date Title
JP5598894B2 (ja) 生物活性を強化した抗体改変体
EP3802606B1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
KR102714455B1 (ko) 이중특이성 재조합단백질 및 이의 응용
CN109843325B (zh) Cd3结合抗体
RU2764559C2 (ru) МУТАНТНЫЕ ВАРИАНТЫ Fc IgG1, ЛИШЕННЫЕ ЭФФЕКТОРНЫХ ФУНКЦИЙ
US9540442B2 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
KR101637502B1 (ko) 치료용 개 면역글로불린 및 이를 이용하는 방법
CN119798453A (zh) 激活免疫细胞的双特异性抗体
TW200808830A (en) Mutant polypeptide having effector function
CN107108718B (zh) 可溶性通用的增强adcc的合成融合基因和融合肽的技术及其应用
JP2023096181A (ja) がん治療のための多重特異性作用物質
WO2023051727A1 (zh) 结合cd3的抗体及其用途
CA3084602A1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
US20250092150A1 (en) Fc polypeptide variants having an increased half-life
JP2022514187A (ja) ＩＶＩＧの代替のための多量体ハイブリッドＦｃ蛋白質
JP2025513230A (ja) 変異体軽鎖フレームワーク領域を備える単鎖可変領域フラグメント
US20250376502A1 (en) Ig-like fusion proteins for treating graves disease
CA3101270C (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
JP2018138022A (ja) ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
RU2800034C2 (ru) Индуцибельные связывающие белки и способы использования
RU2807216C2 (ru) Антитела, связывающие cd3
KR20250054824A (ko) 돼지 항체 돌연변이체
WO2025195443A1 (zh) 特异性结合LIGHT和C5a的多特异性抗体以及组合物及其应用
JP2025535386A (ja) ＴＲＡＩＬまたはＦａｓＬに特異的に結合する抗体の組み合わせおよび二重特異性抗体

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20080829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130221

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140806

R150 Certificate of patent or registration of utility model

Ref document number: 5598894

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees